Daily bars for up to one year, weekly bars for the 5-year view. Averages are 50/200 trading days (10/40 weeks on the 5-year view). Triangles mark past earnings reports, colored by that day’s move; ticks mark ex-dividend dates — hover either for the date. Volume is the shaded bars under the price; switch on RSI or MACD above for a full-history oscillator panel, not just today’s reading.
Reader sentiment, not investment advice. One vote per visitor; click again to change it.
LeMaitre Vascular (LMAT) is trading at $80.99, up 2.57% on the day. Its market value of $1.85B makes it the 2835th largest of the 3132 companies we follow.
It is close to the bottom of its 52-week range ($78.22 to $117.37), 31.0% under the high. Holders are behind 6.5% over twelve months, and down 23.1% across the last three months.
On the chart it has slipped under both the 50-day ($83.78) and 200-day ($94.16) moving averages; RSI is 48, and the last 30 sessions moved at roughly 20% annualized volatility.
The stock changes hands at 28.3 times trailing earnings, 38% below its five-year average of 45.8. The median for its industry group is 31.0.
3 analysts follow the stock and the average call is "buy". The mean target, $107.50, sits 32.7% over where the stock trades.
This summary is put together from the numbers on the page and updates when they do. It describes the data; it is not a forecast or a recommendation.
Composite of 4 factors below, ranked against the 3131 U.S. stocks BeStock covers.
Cheaper than usual on its own 5-year P/E history scores higher.
Higher trailing yield than most of BeStock’s coverage scores higher.
Trading closer to its 52-week high than most peers scores higher.
3 analysts, consensus Buy.
How this is scored: each factor above is a 0–100 percentile rank against every other stock BeStock covers (or, for Wall Street, against the five-point Strong Buy–Sell scale). The overall grade is the plain average of whichever factors apply to this stock — no factor is weighted more than another. That average maps to a letter: A ≥ 85, B ≥ 70, C ≥ 50, D ≥ 30, otherwise F. Recomputed from the data on this page as prices and filings update — it describes where a stock ranks today, not a forecast, and not a BeStock recommendation to buy or sell.
LMAT is not currently one of the 10 holdings in BeStock Momentum, our rules-based momentum strategy.
Since 2021-01-04, the strategy has returned 389% (231.1% for the equal-weight average of BeStock’s coverage over the same stretch). Holdings can change any trading day, not just on a fixed schedule. Backtested performance, updated weekly — not a guarantee of future results, and not a BeStock recommendation.
What Wall Street analysts and Morningstar's fair-value model expect for the stock
Wall Street’s average 12-month target is $107.50, 32.7% above today’s price, with a consensus rating of Buy. Morningstar’s fair value model puts the stock at $95.87, so shares trade 15.5% below that estimate. On earnings multiple, it sits in the 2nd percentile of its own five-year valuation range (cheaper than usual).
Figures are Wall Street analyst consensus and Morningstar’s independent fair-value model, sourced as noted above.
Price return over each window, from adjusted daily and weekly closes
| Indicator | Value | Signal |
|---|---|---|
| Price vs 20-day average | +0.7% | Bullish |
| Price vs 50-day average | -3.3% | Bearish |
| Price vs 200-day average | -14.0% | Bearish |
| 50-day vs 200-day | 50d below 200d | Bearish |
| RSI (14) | 48.0 | Bearish |
| MACD (12,26,9) | -0.60 | Bullish |
| Bollinger band position | 61% | Bullish |
Standard indicator readings worked out from daily closes. They describe how the price has behaved, not where it is going.
Quote as of Oct 6, 2026 6:30 am ET. Prices can lag the live tape. This is background information, not a recommendation.
Ranks are among the 3,131 or so U.S.-listed stocks BeStock covers, recalculated whenever prices refresh. A tile is left out when the measure does not apply, such as yield for a stock that pays no dividend.
Set against the peer table: at 28.3x earnings, LMAT looks expensive against the market, and trades 9% below the 31.0x median among Medical Instruments & Supplies names. The two comparisons do not always agree.
$80.99 is the latest print for LMAT, a move of +2.57% against yesterday's close of $78.96. Today's low and high so far: $78.49 and $81.83.
Equity value comes to $1.85B at the current price. By that measure it is number 2835 of the 3132 names in our coverage.
Buyers pay 28.3 times the last twelve months of profit (EPS $2.52). Averaged over five years the multiple has been 45.8, and today's level ranks in the 2nd percentile of its own history.
The year's floor is $78.22 and the ceiling $117.37. Shares are 31.0% away from that ceiling.
It does. Payouts over the past twelve months work out to a 1.11% yield; the latest ex-dividend date was August 20, 2026.
Of 3 analysts, 67% say buy, 33% hold and 0% sell. Price targets average $107.50, with the most cautious at $95.00 and the most optimistic at $120.00.
BeStock publishes market data and analysis for information only. Nothing here is investment advice or a solicitation to buy or sell any security, and none of it is tailored to your financial situation, goals, or risk tolerance. Quotes may be delayed and figures can contain errors; check primary sources before you trade. How we source and calculate these pages.
No comments yet — be the first to weigh in on LMAT.